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Tumorigenesis is often associated with an unbalanced protein homeostasis (proteostasis) network, which
sensitizes cancer cells to drugs targeting protein quality control (PQC) regulators. In this issue of Cancer
Cell, Anderson and colleagues investigated the anti-cancer activity of a new class of inhibitor against a
multi-functional ATPase essential for proteostasis maintenance.In addition to oncogenic lesions, uncon-
trolled tumor growth is often associated
with heightened reliance on certain non-
oncogenic functions (Luo et al., 2009).
Among them, the protein homeostasis
(proteostasis) network has emerged as a
promising anti-cancer target thanks to
recent success in treatment of multiple
myeloma and mantle cell lymphoma with
the proteasome inhibitors bortezomib
and carfilzomib (Deshaies, 2014).
Proteasome is a multi-subunit protease
that degrades polyubiquitinated proteins.
A major class of proteasome substrates is
misfolded or unassembled polypeptides,
establishing proteasome as a key exec-
utor in proteostasis regulation. Protea-
some also destructs critical factors regu-
lating cell cycle and apoptosis. Thus, it
performs pivotal housekeeping functions
essential for all cell types (Navon and
Ciechanover, 2009). In this regard, the
observation that proteasome inhibitors,
when properly dosed, kills cancer cells
but spares normal cells was surprising.
Naturally, it stimulated a flurry of investi-
gations on the underlying mechanisms,
which helped to formulate the proteosta-
sis addiction theory: tumor cells, owing
to their perturbed proteome landscape,
appear to rely more on the protein quality
control (PQC) network than normal cells
for survival and growth (Deshaies, 2014).
Despite the early success in treating
hematological malignancies, proteasome
inhibitors have displayed little activity
against solid tumors even after numerous
clinical trials using more potent and spe-
cific inhibitors either as a single agent or
in combinatory regimes. The failure might
be partially attributed to the resilience of550 Cancer Cell 28, November 9, 2015 ª201the proteasome system, bolstered by
its abundance and expression plasticity
(inhibition of proteasome induces its
own expression and subsequent activity
recovery) (Deshaies, 2014). Thus, drugs
targeting other components of the PQC
network are needed to overcome the lim-
itations of the existing therapeutics for
proteostasis-addicted tumors.
The study by Anderson et al. (2015) in
this issue of Cancer Cell establishes
p97, a AAA (ATPase associated with
various cellular activities) ATPase at
the heart of proteostasis maintenance,
as a new anti-cancer target. p97 is a
homohexamer; each subunit features
an N-terminal domain followed by two
tandem ATPase domains (D1 and D2).
The D2 domain is responsible for the
majority of the p97 ATPase activity,
whereas D1 appears to make an 30%
contribution (Anderson et al., 2015). As
a highly abundant cellular ATPase tar-
geting a broad spectrum of substrates
for degradation by proteasome, p97
participates in many cellular pathways
including DNA synthesis, DNA damage
response, cell cycle, and membrane
fusion, but a major function of p97 is
to maintain a balanced proteostasis
network through collaboration with the
proteasome in a collection of PQC pro-
cesses including endoplasmic reticu-
lum-associated degradation (ERAD),
ribosome-associated degradation, mito-
chondria-associated degradation, and
nuclear quality control (Figure 1) (Meyer
et al., 2012). Thus, inhibition of p97 might
result in a more favorable outcome
against tumors that do not respond to
proteasome inhibitors.5 Elsevier Inc.Eeyarestatin (EerI) is the first p97 inhib-
itor discovered through characterization
of inhibitors that block ERAD (Wang
et al., 2010). Although the mechanism of
p97 inhibition by EerI is unclear, when
applied to cells in vitro, it induces biolog-
ical hallmarks associated with p97 inhibi-
tion including ERAD inhibition, ER stress
elevation, and apoptosis. As predicted,
EerI has significant cytotoxic activity pref-
erentially against cancer cells isolated
from patients but not healthy cells, and
it displays a robust synergy with Bortezo-
mib in cancer inhibition in vitro (Wang
et al., 2009). The idea of targeting p97
in cancer therapy was further validated
recently with several better-characterized
ATP competitive and allosteric inhibitors
(Chou et al., 2013; Magnaghi et al.,
2013). Although these studies unambigu-
ously establish a strong anti-cancer activ-
ity for p97 inhibitors, due to the lack of
in vivo data, whether p97 inhibition could
achieve similarly desired anti-cancer ef-
fect while without major toxicities in ani-
mals has remained an open question.
By optimizing previously reported p97
inhibitors (Chou et al., 2013), Anderson
et al. (2015) discovered a potent compet-
itive p97 ATPase inhibitor (CB-5083) with
pharmacological properties suitable for
clinical development. CB-5083 specif-
ically inhibits the ATPase activity of the
D2 domain with nanomolar IC50 values.
It is highly selective against p97, as
demonstrated by an ATP displacement
pulldown assay. In this assay, CB-5083
has the strongest effect on ATP binding
to p97 compared to other ATPases and
kinases in a crude cell lysate. The tar-
get specificity was further confirmed by
Figure 1. Roles of p97 in the Cellular Protein Quality Control Network
p97 collaborates with the proteasome in degradation of misfolded ER proteins (the ERAD pathway), defective translation products (ribosome-associated
degradation), misfolded mitochondrial outer membrane proteins (mitochondria-associated degradation), and aberrant nuclear proteins (nuclear quality control).
In ERAD and mitochondria-associated degradation, p97 uses energy from ATP hydrolysis to extract misfolded proteins out of the membrane and target them for
proteasomal degradation. E3, ubiquitin ligase. In the case of ribosome-associated degradation, ribosome-associated p97may release stalled translation product
to facilitate their turnover. In the nucleus, p97 promotes turnover of aberrant nuclear proteins by acting as a chaperone to prevent substrate aggregation.
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lines, most of which were mapped to
the D2 domain near the ATP binding
site. Importantly, reintroducing these mu-
tations to p97 in wild-type cells repro-
duced the resistant phenotype.
As expected, when cancer cells are
exposed to CB-5083, many biological
consequences previously linked to p97
inhibition were detected, including ERAD
inhibition, accumulation of ubiquitinated
proteins, ER stress, and ER stress-medi-ated cell death. Surprisingly, Anderson
et al. (2015) report two observations that
are inconsistent with previous studies.
First, apoptosis induced by CB-5053 is
largely dependent on the ER-associated
death mediator DR5 and the transcription
factor CCAAT/enhancer-binding protein
homologous protein (CHOP), whereas a
previous study established the activa-
tion of the BH3 domain-containing pro-
tein NOXA as a major contributor (Wang
et al., 2010). This discrepancy is probablyCancer Cell 28,more a reflection of the complexity
underlying ER stress-induced cell death
(involving distinctive pathways under
different cellular context) than a refutation
to the previous finding. Another unex-
pected result is that inhibition of p97 by
CB5083 leads to autophagy activation
(based on measuring the stability of one
autophagy substrate) as opposed to inhi-
bition, as suggested previously (Ju et al.,
2009). It remains to be seen whether this
controversy can be resolved when otherNovember 9, 2015 ª2015 Elsevier Inc. 551
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Previewsassays are used to monitor autophagic
activity.
Importantly, the study by Anderson
et al. (2015) demonstrates that, when
tested in mouse xenograft tumor models,
orally applied CB-5083 is well tolerated
and results in a dose-dependent induc-
tion of ER stress and apoptosis in tumor
tissues. Accordingly, the tumor volume
is significantly reduced in several xeno-
graft-based solid tumor mouse models,
whereas, in the same assay, proteasome
inhibitors are barely active. Lastly, the au-
thors close by showing that p97 expres-
sion levels and the Ras-MAPK pathway
activity correlate with the sensitivity to
CB-5083.
Overall, the new p97 inhibitor reported
here will surely serve as another invalu-
able tool to advance our understandings
on the diverse biological mechanisms
regulated by p97. Most significantly, the
demonstration that drugs disrupting the
cellular proteostasis network at another
level can effectively kill cancer cells
derived from solid tumors in mouse
models is a strong testimony to the pro-552 Cancer Cell 28, November 9, 2015 ª201teostasis addition theory, and the findings
reported here will potentially open a new
path to circumvent obstacles in treatment
of solid tumors. In this regard, the study
will certainly prompt tremendous interest
in developing additional p97 inhibitors as
well as inhibitors targeting other proteo-
stasis regulators. Structural validation of
the inhibitor-p97 interactions will certainly
be launched in order to come up with
rational designs to improve p97 inhibitors,
which may overcome the inevitable rise
of resistance to the current inhibitor.
Meanwhile, given the great pharmacolog-
ical property, low toxicity to normal cells,
easy administration route, strong potency,
and high specificity, CB-5083 seems to
have a good chance to endure through
the long and costly clinical testing and
bring significant benefit to patients bearing
proteostasis-addicted tumors.
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Real-time monitoring of changes in cells or cell products released from malignant lesions into the blood has
opened new diagnostic avenues (‘‘liquid biopsy’’). In this issue of Cancer Cell, Best and colleagues describe
that tumor-associated blood platelets provide specific information on the location and molecular composi-
tion of the primary tumor.The peripheral blood of a cancer patient
is a pool of cells and/or cell products
derived from the primary tumor and
different metastatic sites, including cir-
culating tumor cells (CTCs) and stromal
cells of the tumor microenvironment (e.g.,
macrophages) as well as tumor-derived
DNA, RNA, and proteins. The analysis of
these blood components can, therefore,provide a comprehensive real-time picture
of the tumor-associated changes in an in-
dividual cancer patient (Figure 1). This in-
formation can be used for screening and
early detection of cancer, estimation of
the risk for metastatic relapse or progres-
sion (prognostic information), stratification
and real-time monitoring of treatment
response, identification of therapeutic tar-gets and resistance mechanisms (biolog-
ical therapies), and a better understanding
of the biology of metastatic development.
Incontrast to tissuebiopsies,bloodsam-
ples can be obtained easily and repeatedly
from cancer patients. In the last decade,
many reports have focused on CTCs and
circulating nucleic acids (in particular, tu-
mor-derived DNA fragments and various
